Clinical trial / 2010
Saffron matched donepezil in treating mild-to-moderate Alzheimer's disease over 22 weeks.
In a 22-week randomized trial involving 54 community-dwelling adults aged 55 or older with mild-to-moderate Alzheimer's disease, 30 mg daily of saffron showed similar efficacy to 10 mg daily of donepezil. Cognitive subscale and clinical dementia rating scores were the primary outcomes. Overall adverse events occurred at similar rates, although vomiting was significantly more frequent in participants receiving donepezil.
- Study type
- Randomized controlled trial
- Who was studied
- 54 community-dwelling adults aged 55 or older with Alzheimer's disease
- What was measured
- Cognitive and dementia rating scores, adverse events
THE PAPER
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease.
Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. Psychopharmacology (Berl), 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.